undamentalytics Newsletter
Sign in

Lucid Diagnostics Inc. revenue

Lucid Diagnostics Inc.'s revenue was $4.7m in fiscal 2025, up 8.3% on the year before. Since fiscal 2021 ($500,000) it has grown at a compound 75.2% a year. Over the last twelve months it was $5.4m.

Revenue history

US$ thousands unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMJun 2026
Revenue5003772,4284,3464,7065,445
Growth on the year before—−24.6%+544.0%+79.0%+8.3%—
Gross profit500377—−2,753−1,964—
Gross margin100.0%100.0%—−63.3%−41.7%—

Revenue as reported in the company's 10-K and 10-Q filings (for banks, net interest income plus non-interest income). Growth is left blank when the earlier figure was zero or negative.

Revenue against peers

Health Care Equipment: the closest covered companies by revenue. Last twelve months.

CompanyRevenueGrowth3-year growth a year
Lucid Diagnostics Inc. $5.4m 24.9% 90.1%
Neuraxis, Inc $5.3m 65.2% 25.6%
Bioaffinity Technologies, Inc. $5.9m -23.2% -12.2%
Charming Medical Ltd $4.8m -22.7% —
Biomerica Inc $4.3m -11.2% -7.1%
Intelligent BIO Solutions Inc. $4.2m 38.1% 39.0%

Compare with peers

Head to head: LUCD vs NRXSBIAF vs LUCDLUCD vs MCTA

More: Health Care Equipment stocks compared, Health Care sector, rankings of US companies

Figures from Lucid Diagnostics Inc.'s SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Lucid Diagnostics Inc.